Author: Gen News
Source: Gen News
Interest: HistoRx licensed a biomarker-based prognostic melanoma assay from Yale University. It is designed to predict which patients with stage II, node-negative disease have an increased risk of disease recurrence. The assay is based on an automated, quantitative IHC technology called Aqua, which was developed by Yale researchers and which HistoRx is exploiting to develop a range of diagnostics.
Loading...